Karl Tully, MD
@tully_karl
Followers
220
Following
1K
Media
39
Statuses
316
Resident, Department of Urology, Marien Hospital Herne, Germany.
Herne, Deutschland
Joined December 2016
RT @knowuro: 🚀Finally, Urology: Unboxed is fully published in our App! You can now pre-order the physical book. Made for first-year urolog….
0
9
0
RT @thepublishgame: The Publish or Perish Game is a humorous party game about academic publishing. Players race to publish manuscripts with….
0
155
0
Full House für Dr. Peter Bach von @RUBUrology zur Anwendung von DJ Schienen im klinischen Alltag.#DGU24 @dgukongress @BDUrologie
0
0
4
Vincent Hoffman zur Fast Track Steintherapie der Herner FAST 6 Studie 💪🏼💪🏼 #DGU24 @RUBUrology @dgukongress @GeSRU_de
0
0
5
RT @drenriquegrande: 🚨 Exciting Update! 🚨 Our new EVITA (EV Ineligible criTeriA) criteria for identifying patients ineligible for the EV/Pe….
0
62
0
RT @tompowles1: Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had a statistic….
0
100
0
RT @mnaseem2015: One of the most important messages during #eau24. PRIME study. No need for contrast enhancement during MRI for patients wi….
0
2
0
Great talks on Urolithiasis and metastatic urothelial carcinoma by @RUBMedizin @RUBUrology #EAU24 with rising star Vincent Hoffmann. @Uroweb @EurUrolOncol @EUplatinum
0
1
3
RT @niklas_kluemper: T-DXd with 56.3% ORR in HER2 IHC 3+ met. UC 🎯 Important validation that ADC efficacy depends on target gene expression….
0
10
0
RT @AndreaNecchi: 💥 Johnson & Johnson’s Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High….
jnj.com
Breakthrough Therapy Designation for Novel Targeted Releasing System Based on Results from Ongoing Phase 2b SunRISe-1 Study
0
9
0
RT @mvdeimling: Check out our paper @BJUIjournal:.-> no oncologic benefit to extended PLND at RC in cN+ BCa regardless of periop chemo.~ 30….
bjui-journals.onlinelibrary.wiley.com
Objective To determine the oncological impact of extended pelvic lymph node dissection (ePLND) vs standard PLND (sPLND) during radical cystectomy (RC) in clinically lymph node-positive (cN+) bladde...
0
11
0
RT @albisinnidoc: Un percorso per i nostri pazienti @AssPalinuro , per facilitare l’accesso a cure seguendo le linee guida @Uroweb #instill….
0
10
0
RT @DrYukselUrun: 🔘Promising results for bladder-sparing treatment in node-positive bladder cancer! .🔘Equivalent survival outcomes with sur….
0
35
0
RT @drenriquegrande: CheckMate901 is positive👏Awesome news for metastatic UC pts!!!! First time anything beats CISGEM for OS in all patient….
investors.bms.com
CheckMate -901 is the first and only Phase 3 trial with an immunotherapy-based combination to demonstrate a survival benefit compared to standard-of-care cisplatin-based combinations in the first-l...
0
57
0
RT @dr_yakupergun: Modified Glasgow Prognostic Score for Metastatic Renal Cell Carcinoma. 🔍Prognostic and predictive effect of CRP plus alb….
0
9
0
RT @drtanws: Is there any differences between BCG unresponsive relapsing & refractory NMIBC?. We investigated this using our @MDAndersonNew….
0
10
0
RT @DrChoueiri: What an inspiring journey by super star @BWHUrology leader @qdtrinh tackling Health Disparities in prostate cancer! H….
bwhclinicalandresearchnews.org
When Quoc-Dien Trinh, MD, MBA, urologic oncologist in the Brigham’s Division of Urology, is asked what it means to build…
0
9
0
RT @AndreaNecchi: Congrats Moritz Reike and @Decipher_VCYT @ewanagibb for putting light on baseline features of patients relapsing after ne….
0
5
0
RT @drenriquegrande: ⚡️ Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Pts With High-Grad….
0
11
0